Case Report| Volume 16, ISSUE 12, P1694-1696, December 2009

Download started.


A novel use of temozolomide in a patient with malignant prolactinoma


      We report a 64-year-old male who presented to our department in 2007 with bitemporal hemianopia secondary to a large recurrent pituitary prolactinoma in the sellar region and metastatic deposits elsewhere in his neuraxis. He underwent a transphenoidal excision of the large pituitary adenoma which was uncomplicated, although he did suffer from diabetes insipidus post-operatively. He had initially been diagnosed with prolactinoma some years before and had undergone multiple craniotomies to debulk recurrent metastatic lesions. As the patient had already undergone radiotherapy in the past, a novel approach to adjuvant therapy was necessary and he was started on a course of oral chemotherapy, temozolomide, with good results.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Journal of Clinical Neuroscience
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Newlands E.S.
        • Stevens M.F.
        • Wedge S.R.
        • et al.
        Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trials.
        Cancer Treat Rev. 1997; 23: 35-61
        • Neff L.M.
        • Weil M.
        • Cole A.
        • et al.
        Temozolomide in the treatment of an invasive prolactinoma resistant to dopamine agonists.
        Pituitary. 2007; 10: 81
        • Popadic A.
        • Witzmann A.
        • Buchfelder M.
        • et al.
        Malignant prolactinoma: a case report and review of the literature.
        Surg Neurol. 1999; 51: 47-54
        • Lubke D.
        • Saeger W.
        Carcinomas of the pituitary: definition and review of the literature.
        Gen Diagn Pathol. 1995; 141: 81-92
        • Crusius P.S.
        • Forcelini C.M.
        • Mallman A.B.
        • et al.
        Metastatic prolactinoma: case report with immunohistochemical assessment for p53 and Ki-67 antigens.
        Arquivos de Neuropsiquiatria. 2005; 63: 864-869
        • Kars M.
        • Roelfsma F.
        • Romjin J.A.
        • et al.
        Malignant prolactinoma: a case report and review of the literature.
        Eur J Endocrinol. 2006; 155: 523-534
        • Ruebel K.H.
        • Leontovich A.A.
        • Jin L.
        • et al.
        Patterns of gene expression in pituitary carcinomas and adenomas analysed by high-density oligonucleotide arrays, reverse transcriptase quantitative PCR and protein expression.
        Endocrine. 2006; 29: 435-444
        • Spada A.
        • Mantovani G.
        • Lanai A.
        Pathogenesis of prolactinomas.
        Pituitary. 2005; 8: 7-15
        • Hurel S.J.
        • Harris P.E.
        • McNicol A.M.
        • et al.
        Metastatic prolactinoma: effect of octreotide, cabergoline, carboplatin and etoposide; immunocytochemical analysis of proto-oncogene expression.
        J Clin Endocrinol Metab. 1997; 82: 2962-2965
        • Fadul C.E.
        • Kominsky A.L.
        • Meyer L.P.
        • et al.
        Long-term response of pituitary carcinoma to temozolomide. Report of two cases.
        J Neurosurg. 2006; 105: 621-626
        • Kovacs K.
        • Horvath E.
        • Syro L.V.
        • et al.
        Temozolomide therapy in a man with an aggressive prolactin-secreting pituitary neoplasm: morphological findings.
        Hum Pathol. 2007; 38: 526
        • Perry M.C.
        2nd edition. The Chemotherapy Source Book. Vol. 308. Williams and Wilkins, Baltimore1997